We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
77 ELEKTRONIKA

Download Mobile App




First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias

By HospiMedica International staff writers
Posted on 14 May 2024
Print article
Image: The FieldForce Catheter is the first and only contact force PFA catheter optimized for the ventricles (Photo courtesy of Field Medical)
Image: The FieldForce Catheter is the first and only contact force PFA catheter optimized for the ventricles (Photo courtesy of Field Medical)

It is estimated that over 6 million patients in the US and Europe are affected by ventricular arrhythmias, which include conditions such as ventricular tachycardia (VT) and premature ventricular contractions (PVCs). These arrhythmias represent a significant health risk, often leading to sudden cardiac death if not properly managed. Traditional ventricular catheter ablation techniques, such as thermal ablation using conventional radiofrequency (RF) ablation, involve lengthy procedures and carry substantial risks. Now, a new pulsed field ablation (PFA) technology featuring the first and only contact force PFA catheter optimized to work in the ventricle offers a predictable, time-efficient, and safer treatment alternative.

The FieldForce Ablation System from Field Medical (Cardiff, CA, USA) has been specifically developed to overome the limitations of current PFA and RF ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. PFA technology has already significantly changed the treatment landscape for atrial fibrillation (AF) over the past decade. Field Medical’s innovations in PFA technology have made notable advances in cardiac electrophysiology by enhancing safety and reducing the duration of procedures. These advancements have set new industry standards, leading to the broad adoption and transformation of ablation practices. Having demonstrated success in atrial settings, Field Medical is now extending these advancements to treat ventricular arrhythmias, marking a crucial development in the management of complex ventricular cardiac conditions.

Field Medical’s proprietary technology, termed FieldBending, utilizes non-intuitive physics to apply intense, yet brief, electric fields that aim to significantly shorten procedure times safely. The company has initiated its first-in-human study for the FieldForce Ablation System, which will involve up to 60 patients across up to 5 global sites. This VCAS investigational study is essential for demonstrating the safety and efficacy of the FieldForce Ablation System, which is the first contact force PFA system tailored for ventricular ablation. Early trials indicate that the technology can achieve rapid, complete transmural ablation of the left ventricle (LV), providing targeted treatment options and an efficient workflow. Although these findings are preliminary, the potential for this system to fundamentally change the approach to catheter ablation of complex ventricular arrhythmias is immense, possibly exceeding current medical standards.

"Our vision at Field Medical is to transform VT ablation into a widely available, one-hour outpatient procedure with improved safety outcomes," said Steven Mickelsen MD, CEO of Field Medical. "With the promising early data for our VCAS study, in much the same way that PFA transformed AF, the FieldForce Ablation System is optimized to transform how ventricular arrhythmias are treated, offering hope to millions of patients worldwide. With the strong investor support, renown physician engagement and the groundbreaking potential of our technology, we are set to redefine the standards of cardiac ablation once again."

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
FHD Surgical Imaging System
SV-M2K30

Print article

Channels

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more

Business

view channel
Image: The finalists have been announced for the IHF Awards 2024 (Photo courtesy of IHF)

International Hospital Federation Awards 2024 Finalists Announced

The International Hospital Federation (IHF; Geneva, Switzerland) has announced the finalists of the IHF Awards 2024 after the judges completed scoring entries in all 7 Award categories. The IHF Awards... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.